The past few weeks have been like nothing we have ever experienced, the COVID-19 pandemic has disrupted everything from research projects to coffee shop conversations. As a result, Innovative Research has extended the application deadline for the $10,000 grant opportunity to fund Life Science Research from March 31 to May 15, 2020. The winning applicant will still be announced on June 1, 2020.We understand that this is a rapidly evolving situation and we sincerely hope this extension helps to alleviate some of the pressure and competing priorities so many researchers are dealing with right now. Innovative Research remains committed to doing everything we can...
- Tags: news & updates
Hemophilia has been a known bleeding disorder for nearly all of recorded human history, with references as far back as the 2nd century AD. Still, it wasn’t until recent decades that treatments to extend life expectancy and increase quality of life were developed. Today, it is possible for hemophilia patients to live a full and happy life – and outcomes are getting better all the time.
Factor IX is one of the proteins that play a role in coagulation. Produced in the liver and activated by Factor XIa or Factor VIIa, depending on whether the coagulation cascade is following the contact activation pathway or the tissue factor pathway, it then catalyzes the next reaction in the cascade continuing down the path toward clot formation. Factor IX deficiency results in Hemophilia B, a clotting disorder that prevents the blood from clotting appropriately.
A series of sudden and unexplained deaths among seemingly healthy Amish children has been a mystery for years. New technology has allowed researchers to isolate the rare genetic mutation in the RYR2 gene that is to blame, offering answers and hope to the families impacted.
A genetic mutation in SERPINE1, the gene responsible for Plasminogen Activator Inhibitor-1 (PAI-1), seems to have ties back to leading a longer, healthier life. While complete PAI-1 deficiency can lead to a life-threatening clotting disorder, individuals who were heterozygous for this mutation seem to enjoy an extended lifespan on average.